AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
1min snip
Money Talks: Why weight-loss drugs will reshape the world
Money Talks from The Economist
The Lucrative Business of GLP1 Drugs
GLP1 drugs, mainly injection-based and taken weekly, have high list prices in the US, around $16,000 per year. The two leading firms selling these drugs, Novo Nordisk and Eli Lilly, have witnessed a significant increase in their market value, with speculation that one could become the first trillion-dollar pharmaceutical company. The current duopoly in the market is sustained by factors like patents, approvals, and FDA regulations, making it challenging for new entrants to compete in the short to medium term.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode